SphingoTec announces a series of presentations demonstrating the utility of its innovative biomarkers in sepsis, positively impacting diagnostic and treatment decisions for critically ill patients.
Uniklinik RWTH Aachen and SphingoTec GmbH announce today that novel data on the acute care biomarkers bio-ADM and penKid will be presented at the 40th ISICEM.
Diagnostics company SphingoTec GmbH (“SphingoTec”) announces the appointment of Dr. Angelo Moesslang as new chief financial officer (CFO) and managing director.
Diagnostics company SphingoTec GmbH (“SphingoTec”) announces an expansion of its go-to-market strategy to scale its sales in Germany by creating a direct sales force for its integrated diagnostic…
German University Hospital Uniklinik RWTH Aachen and diagnostics company SphingoTec GmbH today announced that the endothelial function biomarker bio-ADM aids in the early risk stratification and…
Diagnostics company SphingoTec GmbH (“SphingoTec”) announced today the first published data (1) on the biomarker DPP3 that can predict the evolution of organ function and survival in septic patients.…
Diagnostics company SphingoTec GmbH announced today that two distinct processes are involved in the development of septic shock and that SphingoTec’s biomarkers for endothelial function (vascular…
SphingoTec GmbH (“SphingoTec”) announced today that the Acute Disease Quality Initiative (ADQI) recommends the use of novel biomarkers for AKI, including functional biomarkers as penKid®.
